keyword
MENU ▼
Read by QxMD icon Read
search

Febrile neutropenia

keyword
https://www.readbyqxmd.com/read/27915301/assessing-the-risk-of-false-positive-serum-galactomannan-among-patients-receiving-piperacillin-tazobactam-for-febrile-neutropenia
#1
Hayati Demiraslan, M Altay Atalay, Esma Eren, Koray Demir, Leylagul Kaynar, A Nedret Koc, Mehmet Doganay
Galactomannan (GM) assay is commonly used as an early diagnostic tool for invasive fungal infection (IFI) in high-risk hematology patients. False positivity is frequently observed in GM with the use of piperacillin/tazobactam. The usage of generic drugs over the original brand has a significant cost advantage. The aim of this study was to assess the performance of GM test among patients receiving original and generic piperacillin/tazobactam formulations. The study included 85 adult patients; 62.4% were male with hematological malignancy currently receiving piperacillin/tazobactam...
December 2, 2016: Medical Mycology: Official Publication of the International Society for Human and Animal Mycology
https://www.readbyqxmd.com/read/27911276/the-mtor-inhibitor-everolimus-in-combination-with-azacitidine-in-patients-with-relapsed-refractory-acute-myeloid-leukemia-a-phase-ib-ii-study
#2
Peter Tan, Ing Soo Tiong, Shaun Fleming, Giovanna Pomilio, Nik Cummings, Mark Droogleever, Julie McManus, Anthony Schwarer, John Catalano, Sushrut Patil, Sharon Avery, Andrew Spencer, Andrew Wei
Therapeutic options are limited in relapsed/refractory acute myeloid leukemia (AML). We evaluated the maximum tolerated dose (MTD) and preliminary efficacy of mammalian target of rapamycin (mTOR) inhibitor, everolimus (days 5-21) in combination with azacitidine 75 mg/m2 subcutaneously (days 1-5 and 8-9 every 28 days) in 40 patients with relapsed (n = 27), primary refractory (n = 11) or elderly patients unfit for intensive chemotherapy (n = 2). MTD was not reached following everolimus dose escalation (2.5, 5 or 10 mg; n = 19) to the 10 mg dose level which was expanded (n = 21)...
November 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27911128/s-1-in-combination-with-docetaxel-and-oxaliplatin-in-patients-with-advanced-gastro-esophageal-adenocarcinoma-two-parallel-phase-1-2a-studies
#3
Per Pfeiffer, Camilla Qvortrup, Merete Krogh, Katrine Schoennemann, Lene W Vestermark, Helle A Jensen, Jon K Bjerregaard
BACKGROUND: Docetaxel in combination with cisplatin and 5-fluorouracil (5-FU) is one of several standard chemotherapy regimens for patients with advanced gastro-esophageal adenocarcinoma (aGEA) in Europe. To enable outpatient treatment, we evaluated the maximum tolerated dose (MTD), recommended dose (RD), dose limiting toxicity (DLT) and safety of docetaxel in combination with oxaliplatin (O) and S-1 (DOS) in Caucasian patients with aGEA. METHODS: We present final results of two parallel phase 1/2a studies (3 + 3 design)...
December 2, 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27908980/phase-2-study-of-eribulin-in-patients-with-previously-treated-advanced-or-metastatic-soft-tissue-sarcoma
#4
Akira Kawai, Nobuhito Araki, Yoichi Naito, Toshifumi Ozaki, Hideshi Sugiura, Yasuo Yazawa, Hideo Morioka, Akihiko Matsumine, Kenichi Saito, Shun Asami, Kazuo Isu
OBJECTIVE: Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. METHODS: This open-label, multicenter, nonrandomized, Phase 2 study enrolled Japanese patients with measurable, advanced/metastatic soft tissue sarcoma of high/intermediate grade and ≥1 prior chemotherapy for advanced disease...
December 1, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27907921/feasibility-of-preoperative-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil-versus-adriamycin-cisplatin-and-5-fluorouracil-for-resectable-advanced-esophageal-cancer
#5
Osamu Shiraishi, Makoto Yamasaki, Tomoki Makino, Masaaki Motoori, Hiroshi Miyata, Masayuki Shinkai, Yutaka Kimura, Motohiro Hirao, Kazumasa Fujitani, Shigeyuki Tamura, Kenji Kobayashi, Masahiko Yano, Yuichiro Doki, Takushi Yasuda
BACKGROUND: Neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma (ESCC) requires reassessment. We have conducted a trial aiming at the comparison between DCF and ACF concerning perioperative adverse events. METHODS: Patients were randomly assigned to receive either DCF [docetaxel 70 mg/m2, cisplatin 70 mg/m2 on day 1, and 5-fluorouracil (5-FU) 700 mg/m2 for 5 days] every 3 weeks or ACF (adriamycin 35 mg/m2, cisplatin 70 mg/m2 on day 1, and 5-FU 700 mg/m2 for 7 days) every 4 weeks...
December 2, 2016: Oncology
https://www.readbyqxmd.com/read/27904453/outcome-of-severe-infections-in-afebrile-neutropenic-cancer-patients
#6
Ksenija Strojnik, Ksenija Mahkovic-Hergouth, Barbara Jezersek Novakovic, Bostjan Seruga
BACKGROUND: In some neutropenic cancer patients fever may be absent despite microbiologically and/or clinically confirmed infection. We hypothesized that afebrile neutropenic cancer patients with severe infections have worse outcome as compared to cancer patients with febrile neutropenia. PATIENTS AND METHODS: We retrospectively analyzed all adult cancer patients with chemotherapy-induced neutropenia and severe infection, who were admitted to the Intensive Care Unit at our cancer center between 2000 and 2011...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27904098/relationship-between-pk-pd-of-cefepime-and-clinical-outcome-in-febrile-neutropenic-patients-with-normal-renal-function
#7
Yoshiko Yamashita, Hidekazu Kamiyama, Asuka Yamamoto, Hiroki Kanoh, Yoshimitsu Yuhki, Akira Ueda, Yukari Kawamoto, Yoshikazu Gotoh, Satoshi Yamamoto
 The efficacy of cefepime (CFPM) is known to depend on the ratio of the time that the serum levels exceed the minimum inhibitory concentration (MIC) to the dosing interval (%T>MIC). The objective of this study was to clarify the relation between %T>MIC and clinical outcome of CFPM, and to identify the optimal dosage regimen. We investigated the outcome of CFPM treatment for febrile neutropenia (FN) patients with normal renal function. Treatment success was defined as the completion of FN therapy with CFPM only...
2016: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/27903924/randomized-phase-ii-study-of-cabazitaxel-versus-methotrexate-in-patients-with-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-previously-treated-with-platinum-based-therapy
#8
Jean-Pascal Henry Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul, Emmanuel Seront, Stéphanie Henry, Lionel D'Hondt, Christophe Lonchay, Stéphane Holbrechts, Petra Boegner, Dany Brohee, Didier Dequanter, Ingrid Louviaux, Brieuc Sautois, Nicolas Whenham, Guy Berchem, Brigitte Vanderschueren, Christel Fontaine, Sandra Schmitz, Aline Gillain, Joelle Schoonjans, Sylvie Rottey
LESSONS LEARNED: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly methotrexate.This phase II study did not meet its primary endpoint.Cabazitaxel has low activity in SCCHN.The toxicity profile in this population also was not favorable owing to the high rate of febrile neutropenia observed (17%)...
November 30, 2016: Oncologist
https://www.readbyqxmd.com/read/27899784/-effectiveness-of-carboplatin-plus-taxane-chemotherapy-for-advanced-or-recurrent-uterine-serous-carcinoma
#9
Takuto Matsuura, Isao Otsuka
OBJECTIVE: Uterine serous carcinoma(USC)is more aggressive compared to endometrioid adenocarcinoma, and often exhibits intraperitoneal spread, resulting in a poor prognosis. It is a rare subtype of uterine cancers, accounting for 5%of cases in Japan; therefore, optimal chemotherapy regimens for patients with advanced or recurrent disease have not been established. In the present study, we evaluated the safety and efficacy of carboplatin plus taxane chemotherapy for the treatment of patients withadvanced and recurrent USC...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27876404/very-early-discharge-compared-with-early-or-non-early-discharge-in-children-with-cancer-and-febrile-neutropenia-a-cochrane-review-summary
#10
Natalie Bradford
No abstract text is available yet for this article.
July 6, 2016: International Journal of Nursing Studies
https://www.readbyqxmd.com/read/27873451/a-prospective-randomized-trial-comparing-piperacillin-tazobactam-with-meropenem-as-empirical-antibiotic-treatment-of-febrile-neutropenic-children-and-adolescents-with-hematologic-and-malignant-disorders
#11
Hirozumi Sano, Ryoji Kobayashi, Daisuke Suzuki, Daiki Hori, Kenji Kishimoto, Kunihiko Kobayashi
BACKGROUND: This randomized prospective study was designed to assess whether piperacillin/tazobactam (PIPC/TAZ) is as effective as meropenem (MEPM) as a first-line antibiotic treatment for febrile neutropenia (FN). PROCEDURE: FN episodes were randomly assigned to receive either PIPC/TAZ (337.5 mg/kg per day in three doses, 1-hr DIV, maximum 13.5 g per day) or MEPM (120 mg/kg per day in three doses, 1-hr DIV, maximum 3 g per day). Clinical responses were evaluated 120 hr after the DIV...
November 22, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27873130/phase-i-clinical-and-pharmacokinetic-study-of-pm01183-a-tetrahydroisoquinoline-lurbinectedin-in-combination-with-gemcitabine-in-patients-with-advanced-solid-tumors
#12
Luis Paz-Ares, Martin Forster, Valentina Boni, Sergio Szyldergemajn, Jesús Corral, Samantha Turnbull, Antonio Cubillo, Carlos Fernandez Teruel, Iker López Calderero, Mariano Siguero, Patrick Bohan, Emiliano Calvo
Background To determine the recommended dose (RD) of a combination of PM01183 and gemcitabine in patients with advanced solid tumors. Methods Forty-five patients received escalating doses of PM01183/gemcitabine on Days 1 and 8 every 3 weeks (d1,8 q3wk) following a standard 3 + 3 design. Results PM01183 3.5 mg flat dose (FD)/gemcitabine 1000 mg/m(2) was the highest dose level tested. Dose-limiting toxicities (DLTs) were mostly hematological and resulted in the expansion of a lower dose level (PM01183 3...
November 21, 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27868411/-efficacy-of-neoadjuvant-chemotherapy-combined-with-bevacizumab-versus-neoadjuvant-chemotherapy-alone-for-her2-negative-breast-cancer-a-meta-analysis-of-randomized-controlled-clinical-trials
#13
Rui Han, Guanying Wang, Yujiao Zhang, Xinhan Zhao
Objective: To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer.Methods: We searched PubMed, the Cochrane Library, Web of Science, CNKI, Wanfang Database and the abstracts of major international conferences in recent 5 years to identify prospective randomized controlled clinical trials that met the inclusion and exclusion criteria. Study selection and analyses were undertaken according to the Cochrane Handbook...
May 25, 2016: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/27868231/aprepitant-in-pediatric-patients-using-moderate-and-highly-emetogenic-protocols-a-systematic-review-and-meta-analyses-of-randomized-controlled-trials
#14
Lucas Miyake Okumura, Fernanda D' Athayde Rodrigues, Maria Angelica Pires Ferreira, Leila Beltrami Moreira
AIMS: To review the efficacy and safety of aprepitant in combination with ondansetron and dexamethasone (triple therapy) in children and adolescents on moderate to highly emetogenic chemotherapy. METHODS: Medline, Embase, Scielo, Lilacs, Cochrane and congress abstracts published until September 2016 were used as data sources. Two reviewers independently selected manuscripts and extracted data. A third reviewer solved discrepancies in study's selection and data extraction...
November 20, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27865372/phase-ii-study-of-panitumumab-and-paclitaxel-as-first-line-treatment-in-recurrent-or-metastatic-head-and-neck-cancer-ttcc-2009-03-vectitax-study
#15
Elvira Del Barco Morillo, Ricard Mesía, Juan Carlos Adansa Klain, Silvia Vázquez Fernández, Joaquina Martínez-Galán, Miguel Pastor Borgoñon, Cyntia González-Rivas, Javier Caballero Daroqui, Alfonso Berrocal, Javier Martínez-Trufero, Ruth Vera, Juan Jesús Cruz-Hernández
OBJECTIVE: To evaluate the activity and safety profile of panitumumab in combination with paclitaxel in patients with recurrent or metastatic SCCHN. MATERIALS AND METHODS: The VECTITAX phase II, open-label, multicenter study included patients with confirmed metastatic and/or recurrent SCCHN deemed to be untreatable by surgery or radiotherapy and ECOG PS=0-1. All patients received paclitaxel (80mg/m(2)/week) and panitumumab (6mg/kg/2weeks) until disease progression or unacceptable toxicity...
November 2016: Oral Oncology
https://www.readbyqxmd.com/read/27863724/-which-approach-of-therapeutic-education-te-for-adolescents-and-young-adults-with-cancer-experience-from-the-te-working-group-of-go-aja
#16
Nadège Corradini, Loïc Dagorne, Marielle Retailleau, Françoise Rédini, Hélène Sudour-Bonnange, Leila Gofti-Laroche, Anne Le Rhun, Nathalie Gaspar
INTRODUCTION: Therapeutic education (TE) is a practice developed over 40 years at an international level to give people with chronic illness the skills necessary to help them better manage their disease. The lengthening survival time of cancer patients as well as changes in the patient-caregiver relationship have contributed to the development of TE in oncologic diseases. Every year in France, about 1900 adolescents and young adults (15-25 years old) are diagnosed with cancer which is the second leading cause of death in this age group...
November 15, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27862097/phase-ib-trial-of-cabazitaxel-and-tasquinimod-in-men-with-heavily-pretreated-metastatic-castration-resistant-prostate-cancer-mcrpc-the-catch-trial
#17
Andrew J Armstrong, Michael S Humeniuk, Patrick Healy, Russell Szmulewitz, Carolyn Winters, Julie Kephart, Michael R Harrison, Elia Martinez, Kelly Mundy, Susan Halabi, Daniel George
BACKGROUND: Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We sought to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tasquinimod in combination with cabazitaxel and prednisone in men with chemorefractory mCRPC. METHODS: Men with mCRPC who had failed prior docetaxel chemotherapy received cabazitaxel 25 mg/m(2) every 3 weeks with oral tasquinimod at 1 of 3 escalating dose levels (0...
November 16, 2016: Prostate
https://www.readbyqxmd.com/read/27860223/validation-of-risk-stratification-for-children-with-febrile-neutropenia-in-a-pediatric-oncology-unit-in-india
#18
Anirban Das, Amita Trehan, Sapna Oberoi, Deepak Bansal
PURPOSE: The study aims to validate a score predicting risk of complications in pediatric patients with chemotherapy-related febrile neutropenia (FN) and evaluate the performance of previously published models for risk stratification. PATIENTS AND METHODS: Children diagnosed with cancer and presenting with FN were evaluated in a prospective single-center study. A score predicting the risk of complications, previously derived in the unit, was validated on a prospective cohort...
November 15, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27858841/marshall-syndrome-in-a-young-child-a-reality-case-report
#19
Laura Mihaela Trandafir, Madalina Ionela Chiriac, Smaranda Diaconescu, Ileana Ioniuc, Ingrith Miron, Daniel Rusu
BACKGROUND: Recurrent fever syndrome, known as the Marshall syndrome (MS), is a clinical entity that includes several clinical features, such as: fever (39-40°C) that occurs repeatedly at variable intervals (3-8 weeks) and in episodes of 3 to 6 days, cervical adenopathy, pharyngitis, and aphthous stomatitis. The diagnosis of MS is one of exclusions; laboratory data is nonspecific and no abnormalities correlated with MS have been detected thus far. METHODS: The authors report the case of a 2-year-old girl admitted to a tertiary pediatric center for repeated episodes of fever with aphthous stomatitis and laterocervical adenopathy...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27858180/irinotecan-monotherapy-as-third-line-treatment-for-advanced-gastric-cancer-refractory-to-fluoropyrimidines-platinum-and-taxanes
#20
Takashi Nishimura, Satoru Iwasa, Kengo Nagashima, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku
BACKGROUND: Because standard chemotherapy for advanced gastric cancer consists of oral fluoropyrimidines plus platinum as first-line therapy, with paclitaxel plus ramucirumab as the second line, irinotecan is usually positioned as third-line chemotherapy in clinical practice in Japan. METHODS: A retrospective evaluation was conducted to determine the efficacy and safety of irinotecan as third-line chemotherapy for advanced gastric cancer in patients refractory or intolerant to fluoropyrimidines, platinum, and taxanes...
November 17, 2016: Gastric Cancer
keyword
keyword
10073
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"